Morningstar

Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications

NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, proudly announces advancements in its intellectual property portfolio ...
Morningstar

Hoth Therapeutics Accepted Into NVIDIA Connect Program, Expanding Its AI and Accelerated Computing Capabilities

NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing breakthrough therapeutics today announced that it has ...
Nasdaq

Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities

NEW YORK, June 5, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company pioneering breakthrough therapies to improve the lives of patients, today ...
Nasdaq

HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal

Shares of Hoth Therapeutics HOTH skyrocketed 178.2% on Tuesday after the company announced positive interim safety and efficacy results from a mid-stage study of its lead candidate, HT-001, which is ...